Biomarin Pharmaceutical (BMRN) Cash & Current Investments (2009 - 2026)

Biomarin Pharmaceutical has disclosed Cash & Current Investments across 18 years of filings, most recently posting $2.2 billion for Q1 2026.

• Quarterly Cash & Current Investments rose 74.67% year-over-year to $2.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 billion (up 74.67% YoY) and the FY2025 annual result came in at $1.6 billion, up 37.17% from the prior year.
• Cash & Current Investments improved to $2.2 billion in Q1 2026, from $1.6 billion in the prior quarter.
• Over five years, Cash & Current Investments peaked at $2.2 billion in Q1 2026 and troughed at $930.4 million in Q3 2024.
• A 5-year average of $1.3 billion and a median of $1.2 billion in 2023 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2024 — Cash & Current Investments retreated 17.36% — and 2026, when it jumped 74.67%.
• Tracing BMRN's Cash & Current Investments over 5 years: stood at $1.3 billion in 2022, then slipped by 16.86% to $1.1 billion in 2023, then grew by 5.95% to $1.1 billion in 2024, then surged by 37.17% to $1.6 billion in 2025, then soared by 42.41% to $2.2 billion in 2026.
• Business Quant data shows BMRN's Cash & Current Investments at $2.2 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.5 billion in Q3 2025.